Markets in Geriatric Medicine: 45+ Market in the United States, Volumes I - III

 
   Hard Copy Mail Delivery - $7,200


Loading...
Published Mar 1, 2004 | Pub ID: KLI910186

Markets in Geriatric Medicine is a collection of reports that address the technologies and markets associated with age-related disorders and diseases. As the American population ages, with the “Baby Boom” generation approaching the age of retirement and Medicare benefits, the incidence and prevalence of age-related disorders is expected to increase proportionate to the increase in the size of the older population segment. This provides a number of challenges, situations of unmet need, and market opportunities for the next two decades.

While the same age-related diseases and disorders are expected to plague the “Baby Boom” generation as other generations, the experience and environment at this time is unlike that which attended previous generations. First, the “Baby Boomer” population presents the largest number of individuals approaching retirement age at one time that has ever occurred before in the United States. Second, the conditions that increase the rate of incidence of many of these age-related diseases and disorders now exist in our society. Third, for the first time in history we have the scientific and medical groundwork and technology to address both the symptoms and causes of these diseases.

The Geriatric Series takes a close look at the major therapeutic opportunities presented by the aging of the “Baby Boom” generation. It considers the epidemiology of these diseases (their incidence and prevalence), current methods and technologies for their treatment, emerging technologies, new research and market trends.

Volume I (published November 2003)deals with rheumatoid arthritis; Volume II (published January 2004)deals with type II diabetes; Volume III (published February 2004) deals with cardiovascular disease.

Volume I: Rheumatoid Arthritis

Chapter One: Executive Summary

  • Background
  • Scope and Methodology
  • Size and Growth of Market
  • Market Trends and Factors

Chapter Two: Introduction

  • Background
  • Population Demographics
  • Epidemiology and Pathology of Rheumatoid Arthritis

Chapter Three: Rheumatoid Arthritis Therapeutics

  • Current Approaches
  • Approaches to Rheumatoid Arthritis Therapy
    • Patient Education
    • Rest and Exercise
    • Diet
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    • Steroids (Corticosteroids, Glucocorticoids)
    • Cytokine Targeted Therapy
    • Other Approaches

  • Emerging Therapeutic Approaches
    • Tumor Necrosis Factor-a (TNF-a) Inhibitors
    • Interleukin-1 (IL-1)Inhibitors
    • p38 MAP Kinase Inhibitors
    • Interleukin-6 (IL-6) Inhibitors
    • Interleukin-15 (IL-15) Inhibitors
    • HC-gp-39 (Human Cartilage-glycoprotein-39) Desensitizers
    • C5 (Complement) Inhibitors
    • Vaccines
    • Other Approaches

Chapter Four: Market Analysis

  • Market Size and Growth
  • Competitive Outlook
  • Market Trends

Chapter Five: Company Profiles

  • Overview
  • Abbott Laboratories
  • AstraZeneca
  • Biogen, Inc.
  • Chugai Pharmaceuticals USA, LLC
  • Corixa Corporation
  • Fujisawa Pharmaceutical Co., Ltd.
  • Lifestyle Therapeutics - Camrose, Inc.
  • Medarex, Inc.
  • Pfizer
  • Schering-Plough
  • Vertex Pharmaceuticals, Inc.
  • Viron Therapeutics, Inc.
  • Wyeth

Chapter Six: Conclusions and Strategic Implications

  • First Conclusion
  • Second Conclusion
  • Third Conclusion
  • Fourth Conclusion
  • Fifth Conclusion
  • Sixth Conclusion
  • Seventh Conclusion
  • Eighth Conclusion
  • Ninth Conclusion
  • Tenth Conclusion

APPENDIX A: Company Directory

List of Exhibits

Chapter One: Executive Summary

  • Table 1-1: Estimated TAM Potential for the Age-Related Segments for Rheumatoid Arthritis Therapeutics in the United States Markets, 2003-2013
  • Table 1-2: Estimated SAM Potential for the Age-Related Segments for Rheumatoid Arthritis Therapeutics in the United States Markets 2003-2013
  • Figure 1-1: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the Middle-Aged and Elderly Market Segments 2003-2013
  • Figure 1-2: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 45- to 54-Year-Old Market Segment 2003-2013
  • Figure 1-3: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 55- to 64-Year-Old Market Segment 2003-2013
  • Figure 1-4: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 65- to 74-Year-Old Market Segment 2003-2013
  • Figure 1-5: Trending in the TAM and SAM Potential for Rheumatoid Arthritis Therapeutics in the United States in the 75+ Year-Old Market Segment 2003-2013

Chapter Two: Introduction

  • Figure 2-1: Growth of the World’s Elderly (60+ Years) Population 2001-2025
  • Figure 2-2: Population Distribution of the United States by Age and Sex 1999 and 2025
  • Figure 2-3: The Growing United States Population 2003-2013
  • Figure 2-4: Increasing Median Age of the United States Population
  • Figure 2-5: Increasing Mean Age of the United States Population
  • Table 2-1: Aging of the United States Population in the Age Groups 45 Years and Older 2003-2013
  • Figure 2-6: Aging Trends in the United States Population for the Age
  • Groups 45 Years and Older 2003-2013
  • Figure 2-7: Changes in the Composition of the 45+Year-Old and Older Age Segment in the United States 2003 and 2013
  • Table 2-2: Older Population Groups as Percentages of the Total United States Population by Age Group 2003-2013
  • Figure 2-8: Aging Trends by Percentage of the United States Population for the Age Groups 45 Years and Older 2003-2013
  • Table 2-3: Prevalence of Rheumatoid Arthritis Cases in the United States
  • for the Total Population and Those 45 Years of Age and Older 2003-2013 Figure 2-9: Trending in United States Rheumatoid Arthritis Cases in the 45+ Year Old Age Group 2003-2013

Chapter Three: Rheumatoid Arthritis Therapeutics

  • Table 3-1: Currently Marketed Products for the Treatment of Rheumatoid Arthritis
  • Table 3-2: Recommended Patient Monitoring for the Administration of DMARDS in the Treatment of Rheumatoid Arthritis Table 3-3: Rheumatoid Arthritis Therapeutics in Development

Chapter Four: Market Analysis

  • Table 4-1: United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics 2003-2013
  • Figure 4-1: Trending in the United States Total and Serviceable
  • Available Market Potential for Rheumatoid Arthritis Therapeutics 2003-2013
  • Table 4-2: United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics in the 45+ Age Population 2003-2013
  • Figure 4-2: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 45- to 54-Year-Old Age Group 2003-2013
  • Figure 4-3: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 55- to 64-Year-Old Age Group 2003-2013
  • Figure 4-4: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 65- to 74-Year-Old Age Group 2003-2013
  • Figure 4-5: Trending in the United States Total and Serviceable Available Market Potential for Rheumatoid Arthritis Therapeutics for the 65- to 74-Year-Old Age Group 2003-2013
  • Table 4-6: Currently Marketed and Potential Competitive Products for the Treatment of Rheumatoid Arthritis

Volume II: Type II Diabetes

CHAPTER ONE: EXECUTIVE SUMMARY

  • Background
  • Scope and Methodology
  • Size and Growth of Market
  • Market Trends and Factors

CHAPTER TWO: INTRODUCTION

  • Background
  • Population Demographics
  • Epidemiology and Pathology of Type II Diabetes

CHAPTER THREE: DIABETES MONITORING

  • Background
  • Glucose Monitoring
  • Hemoglobin A1c
  • Ketone Monitoring
  • Microalbumin Monitoring

CHAPTER FOUR: TYPE II DIABETES THERAPEUTICS

  • Current Approaches to Therapy
    • Patient Education
    • Exercise, Diet and Weight Control
    • Oral Hypoglycemic Agents
    • Insulin

  • Emerging Therapeutic Approaches
    • Prevention
    • Oral Hypoglycemic Agents
    • Insulin
    • Gene Therapy
    • Âeta Cell Transplants

CHAPTER FIVE: MARKET ANALYSIS

  • Market Size and Growth
    • Type II Diabetes Monitoring Markets
    • Insulin Therapy Markets
    • Oral Hypoglycemic Drugs

  • Competitive Outlook
    • Type II Diabetes Monitoring Markets
    • Insulin Therapy Markets
    • Oral Hypoglycemic Drug Markets

  • Market Trends

CHAPTER SIX: COMPANY PROFILES

  • Overview
  • Abbott Laboratories
  • Alkermes, Inc
  • Amylin Pharmaceuticals
  • Aventis Pharma U.S. Division of Aventis
  • The Bayer Group (USA) Subsidiary of Bayer AG
  • Bristol-Myers Squibb1
  • Calyx Therapeutics
  • GlaxoSmithKline
  • Lexicon Genetics Corporation
  • Eli Lilly & Co
  • Metabolex, Inc
  • MitoKor
  • Novo Nordisk
  • Pfizer, Inc
  • Takeda Pharmaceuticals North America
  • Telik, Inc

CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS

  • First Conclusion
  • Second Conclusion
  • Third Conclusion
  • Fourth Conclusion
  • Fifth Conclusion
  • Sixth Conclusion
  • Seventh Conclusion
  • Eighth Conclusion
  • Ninth Conclusion
  • Tenth Conclusion
  • Eleventh Conclusion

APPENDIX: COMPANY DIRECTORY

Volume III: Cardiovascular Disease

Chapter One: Executive Summary

  • Background
  • Hypertension
  • Arteriosclerosis, Atherosclerosis
  • Congestive Heart Failure
  • Scope and Methodology
  • Size and Growth of Market
  • Competitive Picture
  • Market Trends and Factors

Chapter Two: Introduction

  • Background
  • Population Demographics
  • Epidemiology and Pathology of Cardiovascular Diseases
    • Hypertension
    • Arteriosclerosis/Atherosclerosis
    • Congestive Heart Failure
      • Left Ventricular (LV) Failure
      • Right Ventricular (RV) Failure
      • Systolic Dysfunction
      • Diastolic Dysfunction
      • High Output Failure

    • Theories of Congestive Heart Failure
      • Hemodynamic Response Theory
      • Neurohormonal Response Theory
      • Renal Response Theory

    • Conditions Leading to Congestive Heart Failure
      • Myocardial Infarction
      • Hypertension
      • Cardiomyopathy
      • Atrial Fibrillation
      • Other Risk Factors

Chapter Three: Cardiovascular Therapeutics

  • Hypertension and Antihypertensive Drugs
    • ACE Inhibitors
    • á/â(Alpha/Beta)-Blockers
    • Calcium Channel Blockers
    • Diuretics
    • Angiotensin II Receptor Antagonists

  • Atherosclerosis/Arteriosclerosis Therapy
    • Antilipemic Agents
    • Blood Modifiers
      • Anticoagulants
      • Antiplatelet Agents
      • Antithrombin III
      • Thrombin Inhibitors
      • Thrombolytic Agents

    • Surgical Stents
    • Clinical, Business, and Regulatory Developments in Drug-Eluting Stents
    • Alternatives to Drug-Eluting Stents

  • Congestive Heart Failure Treatment
      • Left Ventricular (LV) Failure
      • Right Ventricular (RV) Failure
      • Systolic Dysfunction
      • Diastolic Dysfunction
      • High Output Failure
      • Hemodynamic Response Theory
      • Neurohormonal Response Theory
      • Renal Response Theory

    • ACE Inhibitors and Related Drugs
    • Angiotensin II Receptor Blockers
    • â-Blockers
      • Mild Heart Failure
      • Moderate Heart Failure
      • Severe Heart Failure

    • Diuretics
    • Positive Inotropic Agents
    • Vasodilators
    • Supplements
    • CHF Devices
      • Bridge to Transplant
      • Extended Use
      • Intervention Device Products

  • Emerging Therapeutic Approaches
    • Pharmacological Approaches
      • Atacand® (candesartan cilexetil, AstraZeneca)
      • Avapro® (irbesartan, Bristol-Myers Squibb)
      • Celacade™ (Vasogen)
      • Citicoline (Indevus)
      • CVT-510 (tecadenoson, Cardiovascular Therapeutics)
      • Enoximone (Myogen)
      • Exanta® (ximelagatran, AstraZeneca)
      • Ezetimibe/Simvastatin Tablet (Merck/Schering-Plough)
      • E2F Decoy (Corgentech)
      • HRC 102 (Hemosol Research Corporation)
      • ReoPro® (abciximab, Centocor/Eli Lilly)
      • Sitaxsentan (Encysive Pharmaceuticals)
      • Vanlev® (omapatrilat, Bristol-Myers Squibb)
      • Veletri™ (tezosentan, Actelion)

    • Device Approaches

Chapter Four: Market Analysis

  • Market Size and Growth
    • Overview: The Total Market Potential

  • The 45+-Year-Old Market: A General View
  • Congestive Heart Failure
  • Arteriosclerosis
  • Cardiovascular Market Potentials by Age Sub-Segment
  • Market Potential by Age Sub-Segment within Condition
    • Hypertension
    • Arteriosclerosis
    • Congestive Heart Failure

  • Competitive Outlook
  • Market Trends

Chapter Five: Conclusions And Strategic Implications

  • First Conclusion
  • Second Conclusion
  • Third Conclusion
  • Fourth Conclusion
  • Fifth Conclusion
  • Sixth Conclusion
  • Seventh Conclusion
  • Eighth Conclusion
  • Ninth Conclusion

Chapter Six: Company Profiles

  • Overview
  • Abbott Laboratories
  • Abiomed, Inc.
  • Acorn Cardiovascular, Inc.
  • Actelion, Ltd.
  • Arrow International
  • Astra Zeneca
  • Aventis Pharma USA Division of Aventis
  • Bioheart, Inc.
  • Boston Scientific
  • Bristol-Myers Squibb
  • Cardioenergetics, Inc.
  • Cordis Corporation (A Johnson & Johnson Company)
  • CV Therapeutics
  • Encysive Pharmaceuticals (Formerly Texas Biotechnology Corporation)
  • Geron Corporation
  • GlaxoSmithKline
  • Guidant Corporation
  • Medtronic, Inc.
  • MicroMed Technology, Inc.
  • Myocor, Inc.
  • Myogen
  • Pfizer, Inc.
  • St. Jude Medical
  • Somanetics Corporation
  • Thoratec Corporation

Appendix: Company Directory